Simplified pulse wave velocity measurement in children: Is the pOpmètre valid?

Said Bichali1,* , Alexandra Bruel2, Marion Boivin3, Gwénaëlle Roussey3, Bénédicte Romefort1, Jean-Christophe Rozé4, Emma Allain-Launay2

1 Pediatric Cardiology Unit, Nantes University Hospital, Nantes, France, 2 Pediatric Nephrology Unit, Nantes University Hospital, Nantes, France, 3 Clinical Investigation Center CIC 004, INSERM-Nantes, Nantes University Hospital, Nantes, France, 4 Department of Neonatal Intensive Care, Nantes University Hospital, Nantes, France

* said_b91@hotmail.fr

Abstract

In population exposed to cardiovascular risk, aortic stiffness is an important marker which is assessed by carotid-to-femoral pulse wave velocity (PWV). In childhood, the validated applanation tonometer SphygmoCor® can be used to measure PWV, but is limited in routine practice by the child’s cooperation and operator's experience. An alternative device, the pOpmètre® is validated in adults and rapidly measures finger-to-toe PWV using 2 oxy-meter-like sensors. The aim of this study is to validate the pOpmètre® device in children aged between 4 and 8 years. We compared simultaneous PWV measurements of the two devices, SphygmoCor® and pOpmètre®, in a training group, using the Bland-Altman method. Then we proposed an algorithm to correct pOpmètre® PWV (PWVpop). Finally, we validated this new algorithm in a validation group of children using the Bland-Altman method. This prospective study enrolled 26 children in the training group. Mean PWVpop was 3.919 ± 0.587 m/s and mean SphygmoCor® PWV was 4.280 ± 0.383 m/s, with a difference of -0.362 (CI95%(-0.546;-0.178)) m/s. A new algorithm was defined using transit time (TTpop): corrected PWVpop (m/s) = 0.150/TTpop(s) + 1.381 * Height(m) + 1.148. We enrolled 24 children in the validation group. Mean corrected PWVpop was 4.231 ± 0.189 m/s and mean SphygmoCor® PWV was 4.208 ± 0.296 m/s with a corrected difference of 0.023 (CI95%(-0.086;0.131)) m/s. With this algorithm correction, we found an agreement between PWV measured by the SphygmoCor® and the pOpmètre®, with a difference of less than 10%. Using this algorithm, the pOpmètre® could be used in clinical or research practice in young children exposed to cardiovascular risk. (This study was registered as NCT02991703).

Introduction

Long-term increase in cardiovascular risk has been well established in children with defined pathologies such as diabetes [1], chronic kidney disease (CKD) [2], and in children born pre-term or small for gestational age (SGA) [3]. Multiple parameters are used to estimate this risk,
among which arterial stiffness is highly indicative [4, 5]. The gold standard to evaluate regional arterial stiffness is carotid-to-femoral PWV measured by validated methods including applation tonometry with the SphygmoCor® system in adult population [6–8]. Reference values in healthy 7–8 year old children have been published with normal measured SphygmoCor® PWV (PWVphyg) range between 3.5 m/s and 5.4 m/s [9, 10]. There is no defined pathological threshold in children whereas for adults, above 10 m/s the patient is considered to be at high cardiovascular risk [11]. Moreover, these values are modified by anthropometric factors: age, gender, height [9], blood pressure [12], and ethnic background [13].

In current practice, pulse wave velocity (PWV) is not performed for children at risk of cardiovascular disease because of lack of adapted material. Indeed, the SphygmoCor® is a common device in adult practice, but is limited by its usability, especially in small children who have to remain still, and its requirement of an experienced operator. In children, a more efficient device is necessary. The pOpmètre® instrument, similar to pulse oximeters, utilizes finger and toe pulse wave sensors to measure PWV using photo-plethysmography and can be suitable for use in children [14]. This technique has already been validated to assess digital pulse volume reflecting peripheral pulse pressure [15]. A good correlation with the reference technique has been published and the detection algorithm and signal processing of the pOpmètre® have been improved and validated in adults [16].

The pOpmètre® has not yet been validated in children for PWV measurement. The aim of this prospective single-center study was to demonstrate the value of this device, first in a training group of children aged between 4 and 8. We then compared pOpmètre® and SphygmoCor® PWV measurements in each child and established a new algorithm, and finally validated it in a validation group.

Materials and methods

Ethics statement

The study was registered by the French Commission for Data Protection (National Committee for Informatics and Liberties) and was accepted by the Person Protection Committee (the Ethic authority in the West region in France). The project was registered in ClinicalTrials.gov (Identifier: NCT02991703).

Population

From January to July 2017, we enrolled children aged between 4 and 8, from all pediatric units of the Nantes University Hospital including Outpatient Care, Surgery, General Pediatrics and Pediatric Specialties. In each age range, 12 children were included with a sex ratio of 1:1. Written parental (and child if appropriate) approval was obtained. The child was not included if he or she presented an incompatibility to physiological PWV measurements including pain and agitation making clinical status non-compatible with the measurements, or other situations which could interfere with the peripheral blood flow: compressive bandages on the measured area, peripheral venous catheter or vascular surgery on the right side of the body, vasoconstrictive treatments and temperature less than 36°C. Characteristics of the children, including age, weight, height, peripheral oxygen saturation, signs of good peripheral blood perfusion and heart frequency were noted. The child past medical history of prematurity, SGA, CKD, cardiovascular disease (CVD) or cardiovascular risk factor (CVRF: hypertension, diabetes, dyslipidemia, familial past medical history of cardiovascular disease), and the reason of hospitalization or consultation were also collected.
Number of patients required by group

We decided arbitrarily that the mean difference between the SphygmoCor® and pOpémètre® PWV had to be less than 10% of the PWVsphyg value, which seems acceptable in clinical practice. As the expected PWVsphyg was 4.5 m/s with a standard deviation (SD) of 0.45, the acceptable mean difference was 0.45 m/s between PWVsphyg and pOpémètre® PWV (PWVpop) [9, 13]. This corresponds to the ARTERY society recommendations which consider the accuracy of the tested device as excellent when the mean difference is less than 0.5 m/s [17]. With a power of 90% and an alpha risk of 5%, at least 22 patients were required for each group: the training and validation groups. Taking into account the possible measurement difficulties with the SphygmoCor® device, we decided to include 30 children in each group, totaling in 60 children altogether, with equal number of girls and boys as recommended [17].

Measurement methods

The SphygmoCor® XCEL device (AtCor Medical, Australia) used both a carotid applanation tonometer and a femoral cuff. Although applanation tonometry is considered as the gold standard method, the cuff-based SphygmoCor® XCEL device has been validated in children [18]. It detected carotid and femoral pressure wave form and calculated the delay, called carotid-to-femoral transit time (TTsphyg), between the beginnings of each wave detected successively. Depending on the distance between carotid and femoral pulses, an algorithm transformed this time difference into PWVsphyg. Distances from carotid pulse to cuff upper side and from femoral pulse to cuff upper side were measured after a cuff was put around the right thigh [4].

Other informations were systolic, diastolic and mean arterial pressure on the right arm. Brachial systolic and diastolic blood pressure measurements were taken with a semi-automatic oscillometric device (Dinamap Procare® General Electric, USA).

The pOpémètre® (Axelife sas, France) uses photoplethysmography to detect the arterial pulse waveform in the distal phalanx of the finger and toe. Particular attention was drawn on sensor positioning so that the distal phalanx was in contact with the photodiode. This device measured the pulse wave arrival time difference between the big toe (heart-to-toe TT) and the index finger (heart-to-finger TT) at each heartbeat, called finger-to-toe TT (TTpop) and transformed it into PWVpop [16].

TT and PWV measurements were performed for each child by 2 experienced operators. The child laid back supine with bare feet and arms, at rest in the consultation or hospitalization room [19]. After the SphygmoCor® cuff was put around the right thigh, measurements were started simultaneously on both devices. The carotid-to-femoral distance was measured using the direct method and was multiplied by 80% as recommended [20]. Two SphygmoCor® PWV values were taken and their mean was calculated. At the same time, at least 2 PWV values were taken with the pOpémètre® system on the left side of the body with a third measurement if the difference between the 2 first values was at 0.5 m/s or above. The mean of the 2 closest values on the left side of the body was calculated. This procedure with the pOpémètre® was repeated on the right side after the cuff was taken off. The operators reassured and distracted the child especially when applying the SphygmoCor® carotid probe. The whole procedure was completed in 20 minutes and no follow-up was planned.

Statistical analysis

In the training group, we compared PWVpop and PWVsphyg using the Bland-Altman method. To validate the pOpémètre® device, the primary outcome measure was the mean difference (DiffPopSphyg) between the 2 simultaneous PWVpop and PWVphyg. The pOpémètre® was considered valid if the 95% confidence interval (95% CI) of DiffPopSphyg was less
than 10% of the normal value (ie between -0.450 and +0.450 m/s). We then created an algorithm to calculate the corrected PWVpop. To define the algorithm, we performed a linear regression with PWVshyg as a dependent variable, 1/TTpop and height as independent variables. Coefficients $a$, $b$ and $c$ in the formula $PWV_{shyg} = \frac{a}{TTpop} + b \cdot \text{Height} + c$ were determined. In the validation group, with a Bland-Altman test, we compared PWVshyg and corrected PWVpop, calculated using the algorithm previously defined. Moreover, we performed a sensitivity analysis to include children with aberrant values to the validation group. To assess repeatability, within-patient coefficients of variation were determined for both devices (100°SD/mean). Statistical analyses were performed using SPSS 22.0. Categorical variables were compared using $\chi^2$ test and continuous variables using Student t test. A p value under 0.05 was considered significant. When applicable, data were summarized as mean ± SD.

Results

Population characteristics

After exclusion of 2 children due to non-cooperation of the patient, 60 children had analyzable data with 12 children for each year of age between 4 and 8 years old and a sex ratio of 1:1. We then excluded 10 children from analysis, 4 in the training group and 6 in the validation group, due to SphygmoCor® measuring difficulties (Fig 1). Characteristics of the population in both groups are described in Table 1. A large part of the cohort came from pediatric cardiology or nephrology consultation ($n = 22, 44\%$) and 6 children ($12\%$) had a past medical history of SGA or prematurity.

PWVpop versus PWVshyg in the training group

Among the 26 children of the training group, mean PWVshyg was $4.280 \pm 0.383$ m/s and mean PWVpop was $3.919 \pm 0.587$ m/s (data are available in S1 Table). The 95% CI of DiffPopSphyg was -0.546 to -0.178, inferior to the acceptable limit previously defined. Thus, PWVpop was not validated in the training group, PWVshyg being underestimated (Fig 2).

Corrected PWVpop in the training group

The coefficients given by linear regression were $a = 0.150$, $b = 1.381$ and $c = 1.148$. The equation giving corrected PWVpop depending on TTpop and height with the best agreement between PWVshyg and corrected PWVpop values was then as followed:

$$Corrected\ PWV_{pop}(m/s) = \frac{0.150}{TTpop(s)} + 1.381 \cdot \text{Height}(m) + 1.148$$

Mean corrected PWVpop was $4.280 \pm 0.214$ m/s. The 95% CI of DiffPopSphyg was -0.115 to 0.145, inside the -0.450 to +0.450 interval.

Corrected PWVpop versus PWVshyg in the validation group

We tested the corrected PWVpop in the validation group (data before correction are available in S2 Table). Among the 24 children, mean PWVshyg was $4.208 \pm 0.296$ m/s and mean corrected PWVpop was $4.231 \pm 0.189$ m/s. The 95% CI of DiffPopSphyg was -0.086 to 0.131, inside the -0.450 to +0.450 interval. PWVshyg and corrected PWVpop showed a good agreement (Fig 3). Including the children with aberrant values to the validation group ($n = 30$), the 95% CI of DiffPopSphyg was -0.186 to 0.135, inside the -0.450 to +0.450 interval. Corrected PWVpop and PWVshyg for the 50 children of the 2 groups are presented in Table 2.
Fig 1. Flow chart.

https://doi.org/10.1371/journal.pone.0230817.g001
Repeatability

Within-patient coefficients of variation for repeated measures were 3.1%, 3.2%, and 2.9% for TTpop, TTsphyg and PWVsphyg respectively. Of note, left and right corrected PWVpop showed a very good agreement among the 43 children with available data: mean difference between left and right PWVpop was 0.018 ± 0.214 m/s.

Discussion

We did not find a good agreement before correction between the pOpmêtre® and the SphygmoCor®. However, after correction by a new proposed algorithm, we obtained a good agreement between the 2 devices in children aged between 4 and 8 years old, in a validation group. Thus, it seems that the pOpmêtre®, easy to use in clinic, can be used in this child population.

Detecting signs of arterial stiffness as soon as possible is an issue for pediatric specialists. An appropriate, validated and reproducible method to detecting arterial stiffness in children is highly desirable. Validation of PWV data in children is ethically not feasible with invasive methods; values in healthy children have been published with applanation tonometry using the SphygmoCor® or the PulsePen® and oscillometry using the Vicorder® or the Arteriograph® [21, 22]. These devices have provided comparable PWV results and have been accepted as reference methods in children down to 6 years old [23, 24]. Values in younger children have been published but have not been validated with a method considered as a reference [21, 25]. Moreover, some data were published with formulas extrapolated in young children aged 4 years old with no actual measurement [10, 26].
The pOpmètre® is a photo-plethysmography method validated in adults [14]; here we validated it in comparison with a reference method specifically in young children (4 to 8 years old). Data issued from the training group were initially disappointing. It could be suggested that this poor agreement was influenced by the longer part of the peripheral arterial tree included in the pOpmètre® measure whereas the SphygmoCor® is limited to carotid-to-femoral distance. However in adults, despite this difference, the correlation between TTpop and TTsphyg was excellent using the actual pOpmètre® optimized signal processing that was used in our study [16]. Although the 2 techniques employed different methods, they both aimed at calculating PWV with a good agreement using a new formula.

In adult, studies validating the pOpmètre®, correlation was better with transit time (TT) than PWV [14, 16]. Moreover for children, formulas extrapolating PWV are often based on height [9, 26]. Hence our proposition of algorithm is simple including only TT and height which is available in a common pediatric consultation. Once this correction was applied, good agreement was obtained in the validation group. Furthermore, the pOpmètre® has shown a high right-left reproducibility which increases its usability in daily clinical practice.

The difficulty in measuring TTsphyg and PWVsphyg led to the exclusion of 19% of values in this study. In a study by Keehn et al., data could not be acquired for 22% of children [25]. Indeed, the SphygmoCor® system requires a trained operator and training has shown to
improve measurement success [27, 28]. Children should stay motionless during the procedure which is stressful and hard for the youngest, thus signal remains often suboptimal. In our experience, one whole measurement took at least 10 minutes with 2 experienced investigators. In a

![Fig 3. Bland-Altman graph for the 24 children from the validation group. Mean ± 2 standard deviations = 0.023 ± 0.540 m/s. PWV: pulse wave velocity.](https://doi.org/10.1371/journal.pone.0230817.g003)

| Age and gender (n) | CPWVpop (m/s) | PWVsphyg (m/s) |
|--------------------|---------------|----------------|
| 4 years old (10)   | 4.273 ± 0.215 | 4.256 ± 0.310  |
| 5 years old (10)   | 4.220 ± 0.165 | 4.096 ± 0.373  |
| 6 years old (11)   | 4.196 ± 0.205 | 4.145 ± 0.348  |
| 7 years old (9)    | 4.231 ± 0.158 | 4.284 ± 0.277  |
| 8 years old (10)   | 4.365 ± 0.243 | 4.460 ± 0.332  |
| All children (50)  | 4.256 ± 0.202 | 4.246 ± 0.342  |
| All years, male (23)| 4.272 ± 0.267 | 4.195 ± 0.318  |
| All years, female (27)| 4.243 ± 0.126 | 4.289 ± 0.362  |

Results are presented as mean ± standard deviation.

CPWVpop: corrected pOpmètre® Pulse Wave Velocity, PWVsphyg: SphygmoCor® Pulse Wave Velocity.
A pilot study including 3-to-5-year-old children, 2 nurses were needed to reassure the child with a long procedure of 15 to 30 minutes [29]. This observation limited our use of the SphygmoCor® in pediatrics hence inviting us to find a more reliable and reproducible method. The pOpmètre® was found to be rapid, feasible, acceptable-by-patient and almost operator-independent [14]. It can be utilized by nurses, who commonly use saturation sensors in children. The only well-known limit is coldness of hands and feet causing vasoconstriction necessitating repeated measure, which can be avoided in a warm laboratory or by rubbing cold extremities [15, 30].

PWV data were presented here by age and gender: these PWV data could not be defined as reference values because of the small size and the heterogeneity of the cohort. Each patient was its own control to compare both methods. Despite the past medical history of some children, we could note that our population had morphological parameters (height, weight, body mass index) correlated to their age because their measurements were compared to the World health organization growth charts and were close to the mean values [31].

The necessity and the impact of evaluating aortic stiffness in children younger than 6 years old could be controversial. However, some PWV abnormalities have been described in groups potentially having an increased cardiovascular risk, as in young children with congenital heart diseases and in infants and neonates whose mother have diabetes or hypertension [32–34]. These PWV values were considered abnormal without defined reference values; we therefore think that validating the pOpmètre® in large cohorts of very young children could allow routine PWV measurement. Indeed, during consultation with the specialist pediatrician, a long-term screening and follow-up could be realized in perinatology networks, pediatric nephrology, and pediatric cardiology for an optimal cardiovascular prevention in children [35–39].

To conclude, the pOpmètre® device has been successfully compared to the reference SphygmoCor® in children between 4 and 8 years old using a new algorithm which includes height and TT. This technique seems to be more appropriate than other devices actually validated for routine follow-up. To allow a reliable use of the pOpmètre®, our data need to be validated in larger cohorts of healthy and ill children as results from adults cannot be extrapolated to children [40].

Supporting information

S1 Checklist. TREND statement checklist.
(DOCX)

S1 Table. Pulse wave velocities in the training group.
(PDF)

S2 Table. Pulse wave velocities in the validation group.
(PDF)

Acknowledgments

We thank the pediatric teams of the Children Nantes University Hospital as well as the children and their parents for their kind help during the study. We also acknowledge the persons who took part to rereading and submission.

Author Contributions

Conceptualization: Jean-Christophe Rozé.

Data curation: Marion Boivin, Jean-Christophe Rozé.
Formal analysis: Jean-Christophe Rozé.

Funding acquisition: Jean-Christophe Rozé.

Investigation: Saïd Bichali, Alexandra Bruel, Marion Boivin, Bénédicte Romefort, Jean-Christophe Rozé, Emma Allain-Launay.

Methodology: Saïd Bichali, Marion Boivin, Jean-Christophe Rozé, Emma Allain-Launay.

Project administration: Saïd Bichali, Marion Boivin, Jean-Christophe Rozé, Emma Allain-Launay.

Resources: Saïd Bichali, Marion Boivin, Jean-Christophe Rozé, Emma Allain-Launay.

Software: Saïd Bichali, Marion Boivin, Jean-Christophe Rozé.

Supervision: Saïd Bichali, Alexandra Bruel, Marion Boivin, Gwénaëlle Roussey, Jean-Christophe Rozé, Emma Allain-Launay.

Validation: Saïd Bichali, Marion Boivin, Emma Allain-Launay.

Visualization: Saïd Bichali, Alexandra Bruel, Emma Allain-Launay.

Writing – original draft: Saïd Bichali, Alexandra Bruel, Gwénaëlle Roussey, Jean-Christophe Rozé, Emma Allain-Launay.

Writing – review & editing: Saïd Bichali, Jean-Christophe Rozé, Emma Allain-Launay.

References

1. Dabelea D, Stafford JM, Mayer-Davis EJ, D’Agostino R, Dolan L, Imperatore G, et al. Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood. JAMA. 2017 28; 317(8):825–35.

2. Covic A, Mardare N, Gusbeth-Tatomir P, Brumaru O, Gavrilovici C, Munteanu M, et al. Increased arterial stiffness in children on haemodialysis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc—Eur Ren Assoc. 2006 Mar; 21(3):729–35.

3. Bayman E, Drake AJ, Piyasena C. Prematurity and programming of cardiovascular disease risk: a future challenge for public health? Arch Dis Child Fetal Neonatal Ed. 2014 Nov; 99(6):F510–514. https://doi.org/10.1136/archdischild-2014-306742 PMID: 25135955

4. Laurent S, Boutouryrie P, Asmar R, Gautier I, Laloux B, Guizé L, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001 May; 37(5):1236–41. https://doi.org/10.1161/01.hyp.37.5.1236 PMID: 11358934

5. Boutouryrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension. 2002 Jan; 39(1):10–5. https://doi.org/10.1161/01.hyp.01.02.099031 PMID: 11799071

6. Vlachopoulos C, Aznauridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010 Mar 30; 55(13):1318–27. https://doi.org/10.1016/j.jacc.2009.10.061 PMID: 20338492

7. Laurent S, Marais L, Boutouryrie P. The Noninvasive Assessment of Vascular Aging. Can J Cardiol. 2016; 32(5):669–79. https://doi.org/10.1016/j.cjca.2016.01.039 PMID: 27118294

8. Hwang MH, Yoo JK, Kim HK, Hwang CL, Mackay K, Hemstreet O, et al. Validity and reliability of aortic pulse wave velocity and augmentation index determined by the new cuff-based SphygmoCor Xcel. J Hum Hypertens. 2014 Aug; 28(8):475–81. https://doi.org/10.1038/jhh.2013.144 PMID: 24430704

9. Reusz GS, Csepregal O, Temmar M, Kis E, Cherif AB, Thaleb A, et al. Reference values of pulse wave velocity in healthy children and teenagers. Hypertension. 2010 Aug; 56(2):217–24. https://doi.org/10.1161/HYPTENSIONAH.A.110.152686 PMID: 20566959

10. Curcio S, Garcia-Espinosa V, Arana M, Farro I, Chiesa P, Giachetto G, et al. Growing-Related Changes in Arterial Properties of Healthy Children, Adolescents, and Young Adults Nonexposed to Cardiovascular Risk Factors: Analysis of Gender-Related Differences. Int J Hypertens. 2016; 2016:4982676. https://doi.org/10.1155/2016/4982676 PMID: 26989504
11. Reference Values for Arterial Stiffness Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’. Eur Heart J. 2010 Oct; 31(19):2338–50. doi:10.1093/eurheartj/ehq165 PMID: 20530030

12. Lurbe E, Torro I, Garcia-Vicent C, Alvarez J, Fernández-Fornoso JA, Redon J. Blood Pressure and Obesity Exert Independent Influences on Pulse Wave Velocity in Youth. Hypertension. 2012 Jan 8; 60(2):550–5. doi:10.1161/HYPERTENSIONAHA.112.194746 PMID: 22733475

13. Lefferts WK, Augustine JA, Sparthano NL, Atallah-Yunes NH, Heffernan KS, Gump BB. Racial Differences in Aortic Stiffness in Children. J Pediatr. 2017 Jan; 180:62–7. doi:10.1016/j.jpeds.2016.09.071 PMID: 27817877

14. Alivon M, Vo-Duc Phuong T, Vignon V, Bozec E, Khettab H, Hanon O, et al. A novel device for measuring arterial stiffness using finger-toe pulse wave velocity: Validation study of the pOpmètre®. Arch Cardiovasc Dis. 2015 Apr; 108(4):227–34. doi:10.1016/j.acvd.2014.12.003 PMID: 25682547

15. Millasseau SC, Guigui FG, Kelly RP, Prasad K, Cockcroft JR, Ritter JM, et al. Noninvasive assessment of the digital volume pulse. Comparison with the peripheral pressure pulse. Hypertension. 2000 Dec; 36(6):952–6. doi:10.1161/01.hyp.36.6.952 PMID: 11116106

16. Obeid H, Khettab H, Marais L, Hallab M, Laurent S, Boutouyrie P. Evaluation of arterial stiffness by finger-toe pulse wave velocity: optimization of signal processing and clinical validation. J Hypertens. 2017 Aug; 35(8):1618–25. doi:10.1093/jhj/hjx063 PMID: 28739892

17. Wilkinson IB, McEniery CM, Schillaci G, Boutouyrie P, Segers P, Donald A et al. ARTERY Society guidelines for validation of non-invasive haemodynamic measurement devices: Part 1, arterial pulse wave velocity. Artery Res. 2010 Jun; 4(2):34–40.

18. Stabouli S, Printza N, Zervas C, Dotis J, Chrysaides K, Maliaho A, et al. Comparison of the SphygmoCor XCEL device with applanation tonometry for pulse wave velocity and central blood pressure assessment in youth. J Hypertens. 2019 Jan; 37(1):30–36. doi:10.1097/01.hjh.0000000000001371 PMID: 29939943

19. Foo JYA, Wilson SJ, Williams GR, Coates A, Harris M-A, Cooper DM. Predictive regression equations and clinical uses of peripheral pulse timing characteristics in children. Physiol Meas. 2005 Jun; 26(3):317–28. doi:10.1088/0967-3334/26/3/015 PMID: 15798305

20. Van Bortel LM, Laurent S, Boutouyrie P, Chowiencizyk P, Cruickshank JK, De Backer T, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens. 2012 Mar; 30(3):445–8. doi:10.1097/JHJ.0b013e328359562c PMID: 23006045

21. Thurn D, Doyon A, Sözen B, Bayazit AK, Canpolat N, Duzova A, et al. Aortic Pulse Wave Velocity in Healthy Children and Adolescents: Reference Values for the Vicorder Device and Modifying Factors. Am J Hypertens. 2015 Dec; 28(12):1480–8. doi:10.1093/ajh/hpv048 PMID: 25944878

22. Hidvégi EV, Illýés M, Benczúr B, Bőcskei RM, Rátgéber L, Lenkey Z, et al. Reference values of aortic pulse wave velocity in a large healthy population aged between 3 and 18 years. J Hypertens. 2012 Dec; 30(12):2314–21. doi:10.1093/jhj/hjs181 PMID: 22990356

23. Kiss E, Csepregkíl O, Kerti A, Salvi P, Benetos A, Tisler A, et al. Measurement of pulse wave velocity in children and young adults: a comparative study using three different devices. Hypertens Res. 2011 Nov; 34(11):1197–202. doi:10.1080/13885470.2011.103 PMID: 21766122

24. Kracht D, Shroff R, Baig S, Doyon A, Jacobi C, Zeller R, et al. Validating a New Oscillometric Device for Aortic Pulse Wave Velocity Measurements in Children and Adolescents. Am J Hypertens. 2011 Jan 12; 24(12):1294–9. doi:10.1038/ajh.2011.147 PMID: 21866186

25. Keehn L, Milne L, McNeill K, Chowiencizyk P, Sinha MD. Measurement of pulse wave velocity in children: comparison of volumetric and tonometric sensors, brachial-femoral and carotid-femoral pathways. J Hypertens. 2014 Jul; 32(7):1464. doi:10.1097/JHJ.0000000000000203 PMID: 24759123

26. Mora-Urda A1, Molina MDCB, Mill JG, Monterro-López P. Carotid-Femoral Pulse Wave Velocity in Healthy Spanish Children: Reference Percentile Curves. J Clin Hypertens Greenwic h Conn. 2017 Mar; 19(3):227–34.

27. Lowenthal A, Evans JMA, Punn R, Nourse SE, Vu CN, Popat RA, et al. Arterial application tonometry: feasibility and reproducibility in children and adolescents. Am J Hypertens. 2014 Sep; 27(9):1218–24. doi:10.1093/ajh/hpu034 PMID: 24627445

28. Sigrist MK, Chiarelli G, Levin A, Romann A, Weber C. Pulse wave velocity measurements are reproducible in multiple trained observers: a short report. Nephron Clin Pract. 2010; 116(1):c60–4. doi:10.1159/000314664 PMID: 20502040

29. Ghazi L, Dudenhoestel T, Xing D, Ejem D, Turner-Henson A, Joiner CI, et al. Assessment of vascular function in low socioeconomic status preschool children: a pilot study. J Am Soc Hypertens JASH. 2017 Feb; 11(2):101–9. doi:10.1016/j.jash.2016.12.006 PMID: 28063913
30. Lund F. Digital pulse plethysmography (DPP) in studies of the hemodynamic response to nitrates—a survey of recording methods and principles of analysis. Acta Pharmacol Toxicol (Copenh). 1986; 59 Suppl 6:79–96.

31. Scherdel P, Botton J, Rolland-Cachera M-F, Léger J, Pelé F, Ancel PY, et al. Should the WHO growth charts be used in France? PloS One. 2015; 10(3):e0120806. https://doi.org/10.1371/journal.pone.0120806 PMID: 25761138

32. Seki M, Kurushima C, Kawasaki H, Masutani S, Senzaki H. Aortic stiffness and aortic dilation in infants and children with tetralogy of Fallot before corrective surgery: evidence for intrinsically abnormal aortic mechanical property. Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg. 2012 Feb; 41(2):277–82.

33. Chen S, Chetty S, Lowenthal A, Evans JM, Vu C, Stauffer KJ, et al. Feasibility of neonatal pulse wave velocity and association with maternal hemoglobin A1c. Neonatology. 2015; 107(1):20–6. https://doi.org/10.1159/000366467 PMID: 25301402

34. Koudsi A, Oldroyd J, McElduff P, Banerjee M, Vyas A, Cruickshank JK. Maternal and neonatal influences on, and reproducibility of, neonatal aortic pulse wave velocity. Hypertens Dallas Tex 1979. 2007 Jan; 49(2):225–31.

35. Odri Komazec I, Posod A, Schwienbacher M, Resch M, Pupp Peglow U, Kiechl S, et al. Aortic Elastic Properties in Preschool Children Born Preterm. Arterioscler Thromb Vasc Biol. 2016 Nov; 36(11):2268–74. https://doi.org/10.1161/ATVBAHA.116.308144 PMID: 27659099

36. Demicheva E, Crispi F. Long-term follow-up of intrauterine growth restriction: cardiovascular disorders. Fetal Diagn Ther. 2014; 36(2):143–53. https://doi.org/10.1159/000353633 PMID: 23948759

37. Vieux R, Gerard M, Roussel A, Sow A, Gatin A, Guillemin F, et al. Kidneys in 5-year-old preterm-born children: a longitudinal cohort monitoring of renal function. Pediatr Res. 2017 Dec; 82(6):979–85. https://doi.org/10.1038/pr.2017.148 PMID: 28665930

38. Vieux R, Hascoët J-M, Franck P, Guillemin F. Increased albuminuria in 4-year-old preterm-born children with normal height. J Pediatr. 2012 Jun; 160(6):923–928.e1. https://doi.org/10.1016/j.jpeds.2011.12.005 PMID: 22261507

39. Borchert-Mörlins B, Thurn D, Schmidt BMW, Büscher AK, Oh J, Kier T, et al. Factors associated with cardiovascular target organ damage in children after renal transplantation. Pediatr Nephrol Berl Ger. 2017 Nov; 32(11):2143–54.

40. Edgell H, Stickland MK, and MacLean JE. A simplified measurement of pulse wave velocity is not inferior to standard measurement in young adults and children. Blood Press Monit. 2016 Jun; 21(3):192–95. https://doi.org/10.1097/MBP.0000000000000183 PMID: 26905286